This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

LSX USA Congress
Life Science Executive Partnering
Congress Sept 23-24, Forums Sept 22, 2026Hynes Convention Center, Boston, USA

Bibhash Mukhopadhyay
CEO, Sapient Biotech Investments at Sapient Biotech Investments; Miletus Biotechnology
Speaker

Profile

Bibhash is an investment fund manager, investor, company builder and board member with almost 2 decades of experience in biotech. He is the CEO of Sapient Biotech, which is currently building a sector-specialized investment fund that invests exclusively in biotech companies, both private and small-cap public, with a fundamental, bottom-up, absolute-return strategy. It is also building a fund focused on rare diseases with a double bottom-line mandate for return on mission and return on investment. Through DW Wealth Management, he advises various Family Offices and Disease foundations on investing in the healthcare sector, either by seeding new funds or directly into companies. Previously, he was a co-founder and GP in Sound Bioventures and an investor with the biotech practice of a large, diversified venture fund, NEA. Prior to that he has operating experience in business development, portfolio management and corporate strategy functions at both AstraZeneca and Johnson & Johnson. He has led, managed and exited multiple private and public biotech investments, participated in multiple major in-licensing, divestiture and acquisitions and cross-border Europe / US deals and has had advisory roles in several life science incubators and healthcare delivery non-profits. His education spans 3 continents culminating with a PhD in the biology of retinal degeneration from Baylor College of Medicine.

Bibhash Mukhopadhyay's Network

Agenda Sessions

  • Decoding the Biotech VC Mindset: How Investors Are Choosing Deals Now

    2:25pm